Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 8/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SAT1 | P21673 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18236761 | 0.86 | EPHX1 (0.61) | EPHX1ACHEKMT2ACYP2C19MEN1 | |
| SCHEMBL20362858 | 0.86 | EPHX1 (0.46) | EPHX1ACHEKMT2AMEN1TSHR | |
| SCHEMBL3190326 | 0.84 | EPHX1 (0.61) | EPHX1ACHEKMT2AMEN1TSHR | |
| SCHEMBL20095052 | 0.84 | EPHX1 (0.57) | EPHX1ACHEKMT2AMEN1 | |
| SCHEMBL464489 | 0.81 | EPHX1 (0.46) | EPHX1ACHETSHR | |
| SCHEMBL14872684 | 0.80 | EPHX1 (0.64) | EPHX1ACHETSHR | |
| SCHEMBL20095029 | 0.80 | EPHX1 (0.64) | EPHX1ACHETSHR | |
| SCHEMBL1028062 | 0.79 | TDP1 (0.55) | EPHX1KMT2AMEN1 | |
| SCHEMBL13431320 | 0.78 | — | — | |
| SCHEMBL28007905 | 0.77 | EPHX1 (0.50) | EPHX1ACHEKMT2ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580919-B2 | Polymer conjugates of GLP-1 | NEKTAR THERAPEUTICS (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130096258-A1 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS (US) | 2013-04-18 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096258-A1 | POLYMER CONJUGATES OF GLP-1 | GLP1R, GIPR, NGLY1 | EPHX1 3362/4885ACHE 2869/4885KMT2A 704/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | EPHX1 1924/4885ACHE 1324/4885KMT2A 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.